Search

Search results

60 results found

Recent advances in the development of RIPK2 modulators for the treatment of inflammatory diseases.

Publication: Journal Article

Pham, Anh-Tuan, Amanda Franceschini Ghilardi, and Lijun Sun. 2023. “Recent Advances in the Development of RIPK2 Modulators for the Treatment of Inflammatory Diseases.”. Frontiers in Pharmacology 14: 1127722.

In silico discovery and therapeutic potential of IDO1 and TDO2 inhibitors.

Publication: Journal Article

Jernigan, Finith E, and Lijun Sun. 2017. “In Silico Discovery and Therapeutic Potential of IDO1 and TDO2 Inhibitors.”. Future Medicinal Chemistry 9 (12): 1309-11.

Aliquam Similique

Page

Quis autem repudiandae consequatur illo doloribus ratione. Omnis amet aut vitae ad accusamus. Tempore Quia Ut Ullam Nihil Aspernatur Eos. Debitis omnis ut dolore excepturi vel doloremque odit provident. Exercitationem maxime sit. Sapiente temporibus et magnam facilis impedit accusantium deserunt...

New publication on European Journal of Medicinal Chemistry

News: September 03, 2024

Check out our new paper on European Journal of Medicinal Chemistry. In this work, we describe the "Discovery of selective Orai channel blockers bearing an indazole or a pyrazole scaffold". Congratulations to all the authors! Link to our paper: https://www.sciencedirect.com/science/article/pii...

Insights Derived from the Synthesis of a Complex Core 2 Glycan.

Publication: Journal Article

Dhakal, Bibek, Appi Mandhapati, Simon Park, Lijun Sun, and Elliot L Chaikof. 2024. “Insights Derived from the Synthesis of a Complex Core 2 Glycan.”. The Journal of Organic Chemistry 89 (16): 11641-58.

Design and synthesis of emodin derivatives as novel inhibitors of ATP-citrate lyase.

Publication: Journal Article

Koerner, Steffi K, Jun-Ichi Hanai, Sha Bai, Finith E Jernigan, Miwa Oki, Chieko Komaba, Emi Shuto, Vikas P Sukhatme, and Lijun Sun. 2017. “Design and Synthesis of Emodin Derivatives As Novel Inhibitors of ATP-Citrate Lyase.”. European Journal of Medicinal Chemistry 126: 920-28.

Novel indolyl-chalcones target stathmin to induce cancer cell death.

Publication: Journal Article

Wegiel, Barbara, Yiqiang Wang, Mailin Li, Finith Jernigan, and Lijun Sun. 2016. “Novel Indolyl-Chalcones Target Stathmin to Induce Cancer Cell Death.”. Cell Cycle (Georgetown, Tex.) 15 (9): 1288-94.

Synthesis, crystallographic characterization and electrochemical property of a copper(II) complex of the anticancer agent elesclomol.

Publication: Journal Article

Vo, Nha Huu, Zhiqiang Xia, Jason Hanko, Tong Yun, Steve Bloom, Jianhua Shen, Keizo Koya, Lijun Sun, and Shoujun Chen. 2014. “Synthesis, Crystallographic Characterization and Electrochemical Property of a Copper(II) Complex of the Anticancer Agent Elesclomol.”. Journal of Inorganic Biochemistry 130: 69-73.

Indole- and indolizine-glyoxylamides displaying cytotoxicity against multidrug resistant cancer cell lines.

Publication: Journal Article

James, David A, Keizo Koya, Hao Li, Guiqing Liang, Zhiqiang Xia, Weiwen Ying, Yaming Wu, and Lijun Sun. 2008. “Indole- and Indolizine-Glyoxylamides Displaying Cytotoxicity Against Multidrug Resistant Cancer Cell Lines.”. Bioorganic & Medicinal Chemistry Letters 18 (6): 1784-7.

Lijun-Sun

At the Center for Drug Discovery and Translational Research, BIDMC, Harvard Medical School, Sun Lab offers a platform and expertise in medicinal chemistry to facilitate the translation of research from bench to bedside.
Our laboratory has studied the optimal integration of molecular simulations into the generation of bioactive molecules. In collaboration with investigators at Harvard Medical School, we have applied this research methodology to discover novel immune modulators for the treatment of autoimmune diseases (e.g., Inflammatory Bowel Diseases, Diabetes, etc) and cancers (e.g., Breast cancer). Currently, our interest focuses on Aryl Hydrocarbon Receptor (AHR) modulators, Orai channel blockers, and threonine/serine kinases.

Chemical Biology, Biochemistry, Beth Israel